Financial Data and Key Metrics Changes - Revenue for fiscal year 2024 totaled $28.34 million, an increase of 32.9% from fiscal year 2023 [2] - Adjusted EBITDA for fiscal year 2024 was $8.9 million, an 8.9% increase year over year [2][18] - Fourth quarter 2024 revenue increased by 59.2% to $9.1 million compared to $5.7 million in Q4 2023 [18] - Net income for fiscal year 2024 increased by 258% to $2.2 million, or $0.33 per diluted share [17] Business Line Data and Key Metrics Changes - Revenue from direct patient services segment was $12.6 million for fiscal year 2024, a 253% increase from $3.4 million in fiscal year 2023 [13][14] - Revenue from the equipment leasing segment decreased to $15.6 million from $17.8 million in fiscal year 2023 [14] - Gamma Knife revenue declined by 11.6% to $9.7 million for fiscal year 2024 [14] - Proton beam therapy revenue decreased by 1.8% to $10 million in fiscal year 2024 [15] Market Data and Key Metrics Changes - The company has established its first direct patient services cancer treatment centers in the U.S. with the acquisition of three centers in Rhode Island [11] - The international business segment is expected to see continued growth, particularly in Ecuador and the newly opened center in Puebla, Mexico [9][10] Company Strategy and Development Direction - The company is transitioning from a cancer treatment equipment leasing focus to a more patient-centric service model [1] - Strategic initiatives include expanding the footprint in Rhode Island and establishing new treatment centers in Mexico [10][11] - The company has received CON approval to build a fourth radiation therapy center and the first proton beam therapy center in Rhode Island [11][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth strategy and the ability to navigate industry challenges [39][40] - The recent acquisition and operational efficiencies are expected to enhance service quality and accessibility [39] - Management anticipates stronger international growth and increased treatment volumes in the coming years [10][12] Other Important Information - The company ended the year with cash and cash equivalents of $11.3 million, down from $13.8 million at the end of 2023 [25] - Shareholders' equity increased to $25.2 million, or $3.92 per outstanding share, compared to $22.6 million, or $3.59 per outstanding share, at the end of 2023 [25] Q&A Session Summary Question: Benefits of expanding footprint in Rhode Island - The expansion in Rhode Island is expected to create synergies with Brown University Health and other healthcare systems, enhancing cancer care provision [32][33]